IBL | Indrayani Biotech Limited
Inclusive Growth

Date: 14-02-2022

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited,
Floor 25, P J Tower, Dalal Street,
Mumbai - 400001.

(Scrip code: 526445)

Dear Sir/Madam,

Sub: Covering Letter

Ref: Scrip code - 526445

Please find attached Board Outcome for the meeting of Board of directors of the Company held on 14th February, 2022.

Kindly take the same on your records.

Yours Sincerely,

For Indrayani Biotech Limited

INDRAYANI BIOTECH LTD.

R Charu Latha
Company Secretary & Compliance officer

Indrayani Biotech Limited
Inclusive Growth

Date: 14-02-2022

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited,
Floor 25, P J Tower, Dalal Street,
Mumbai - 400001.
Dear Sir/Madam,

Sub: Outcome of the Board meeting
Ref: Scrip code – 526445

Dear Sir/Madam,

This is to inform you that pursuant to Regulation 30 and Regulation 33 of SEBI (LODR), Regulations 2015, the meeting of Board of Directors of the company held on 14th February, **2022** i.e. today, inter alia considered and approved the following agenda:

1. The Unaudited Standalone and Consolidated Financial Results with the Limited Review Report of the statutory auditors of the company for the quarter ended 31st December, 2021(Q3).
2. Mr. Krishnamurthi Ravichandran (M. No: A12838), Practicing Company secretary has been appointed as the Secretarial auditor of the Company for the Financial Year – 2021-22 pursuant to section 204 and Rule 8 of the Companies (Meetings of Board and its powers) Rules, 2014 of Companies Act, 2013.

The meeting commenced at 3.00 pm and concluded at **5.15** pm.

Kindly take the same on your records.

Thanking you

Yours Sincerely,

For Indrayani Biotech Limited

INDRAYANI BIOTECH LTD.

R Charu Latha
Company Secretary & Compliance officer

INDRAYANI BIOTECH LIMITED

Regd. Office :

Block 1 Module No.33, 3rd Floor,SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE,GUINDY CHENNAI - 600032

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 31st DECEMBER 2021

Rs. In Lakhs

		STANDALONE						CONSOLIDATED					
		Quarter Ended			Period Ended		Year Ended	Quarter Ended			Period Ended		Year Ended
Sr No	PARTICULARS	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
A	Date of start of reporting period	01-10-2021	01-07-2021	01-10-2020	01-04-2021	01-04-2020	01-04-2020	01-10-2021	01-07-2021	01-10-2020	01-04-2021	01-04-2020	01-04-2020
B	Date of end of reporting period	31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	31-03-2021	31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	31-03-2021
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income from Operations**												
	(a) Net Sales/Revenue from Operations	1,463.31	1,430.99	580.76	4,318.70	1,392.60	2,100.73	1,525.06	1,485.24	580.76	4,432.50	1,392.60	2,108.84
	(b) Other Income	15.29	3.70	1.18	21.52	11.59	26.34	15.29	3.70	1.18	21.55	11.59	26.50
	Total Income from Operations	**1,478.59**	**1,434.69**	**581.95**	**4,340.22**	**1,404.19**	**2,127.07**	**1,540.35**	**1,488.95**	**581.95**	**4,454.05**	**1,404.19**	**2,135.34**
										-		-	
2	**Expenses**									-		-	
	(a) Cost of Materials consumed	973.24	954.64	305.40	2,868.48	1,093.70	1,575.90	979.47	969.90	305.40	2,881.03	1,093.70	1,577.15
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-		-			-		-	
	(c) Employee benefits expenses	233.75	254.79	112.22	767.77	468.87	571.19	266.72	279.24	112.22	840.67	468.87	594.40
	(d) Finance Costs	59.27	52.90	35.48	144.42	95.90	196.14	59.27	52.90	35.48	144.42	95.90	196.14
	(e) Depreciation and amortisation expense	8.86	8.46	22.29	25.73	64.78	40.25	26.69	10.72	22.29	48.07	64.78	45.82
	(f) Other expenses	85.63	53.80	71.31	226.54	267.98	421.28	93.45	72.02	71.31	257.66	267.98	432.55
	Total Expenses	**1,360.76**	**1,324.60**	**546.70**	**4,032.93**	**1,991.23**	**2,804.76**	**1,425.60**	**1,384.79**	**546.70**	**4,171.84**	**1,991.23**	**2,846.08**
3	**Total profit / (Loss) before exceptional items and tax**	**117.83**	**110.09**	**35.25**	**307.29**	**(587.04)**	**(677.70)**	**114.75**	**104.15**	**35.25**	**282.21**	**(587.04)**	**(710.74)**
4	Exceptional Items		-	(209.74)		(209.74)	(410.98)	-	-	(209.74)		(209.74)	(410.98)
	Add:Share of Profit In Associates							**(0.21)**	**(0.14)**	-	0.85	-	0.28
5	**Total profit / (Loss) before tax**	**117.83**	**110.09**	**(174.49)**	**307.29**	**(796.78)**	**(1,088.67)**	**114.53**	**104.01**	**(174.49)**	**283.06**	**(796.78)**	**(1,121.44)**
6	**Total profit / (Loss) before tax**									-		-	
7	**Tax Expenses**									-		-	
	Current Tax									-		-	
	Deferred Tax									-		-	
	Total Tax Expenses									-		-	
8	**Net Profit Loss for the period from continuing operations**	**117.83**	**110.09**	**(174.49)**	**307.29**	**(796.78)**	**(1,088.67)**	**114.53**	**104.01**	**(174.49)**	**283.06**	**(796.78)**	**(1,121.44)**

INDRAYANI BIOTECH LTD.

9	**Profit (loss) from discontinued operations before tax**									-		-	
10	**Tax expense of discontinued operations**									-		-	
11	**Net profit (loss) from discontinued operation after tax**									-		-	
12	**Share of profit (loss) of associates and joint ventures accounted for using equity method**									-		-	
13	**Total profit (loss) for period**	**117.83**	**110.09**	**(174.49)**	**307.29**	**(796.78)**	**(1,088.67)**	**114.53**	**104.01**	**(174.49)**	**283.06**	**(796.78)**	**(1,121.44)**
14	**Other comprehensive income net of taxes**									-		-	
15	**Total Comprehensive income for the period attributable to**	**117.83**	**110.09**	**(174.49)**	**307.29**	**(796.78)**	**(1,088.67)**	**114.53**	**104.01**	**(174.49)**	**283.06**	**(796.78)**	**(1,121.44)**
	Comprehensive income for the period attributable to owners of parent	117.83	110.09	(174.49)	307.29	(796.78)	(1,088.67)	118.37	106.42	-	292.03	-	**(1,112.15)**
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests							(3.83)	(2.41)	-	(8.97)	-	(9.29)
16	**Details of equity share capital**									-		-	
	Paid-up equity share capital	**3,422.72**	**3,422.72**	**3,422.72**	**3,422.72**	**3,422.72**	**3,422.72**	**3,422.72**	**3,422.72**	**3,422.72**	**3,422.72**	**3,422.72**	**3,422.72**
	Face value of equity share capital	**10.00**	**10.00**	**10.00**	**10.00**	**10.00**	**10.00**	**10.00**	**10.00**	**10.00**	**10.00**	**10.00**	**10.00**
17	**Details of debt securities**									-		-	
	Paid-up debt capital									-		-	
	Face value of debt securities									-		-	
18	**Reserves excluding revaluation reserve**									-		-	
19	**Debenture redemption reserve**									-		-	
20	**Earnings per share**									-		-	
i	**Earnings per equity share for continuing operations**	**0.34**	**0.32**	**(0.51)**	**0.90**	**(2.33)**	**(3.18)**	**0.33**	**0.30**	**(0.51)**	**0.83**	**(2.33)**	**(5.52)**
	Basic earnings (loss) per share from continuing operations	**0.34**	**0.32**	**(0.51)**	**0.90**	**(2.33)**	**(3.18)**	**0.33**	**0.30**	**(0.51)**	**0.83**	**(2.33)**	**(5.52)**
	Diluted earnings (loss) per share from continuing operations									-		-	
ii	**Earnings per equity share for discontinued operations**									-		-	
	Basic earnings (loss) per share from discontinued operations									-		-	
	Diluted earnings (loss) per share from discontinued operations									-		-	
iii	**Earnings per equity share**									-		-	
	Basic earnings (loss) per share from continuing and discontinued operations	**0.34**	**0.32**	**(0.51)**	**0.90**	**(2.33)**	**(3.18)**	**0.33**	**0.30**	**(0.51)**	**0.83**	**(2.33)**	**(5.52)**
	Diluted earnings (loss) per share from continuing and discontinued operations	**0.34**	**0.32**	**(0.51)**	**0.90**	**(2.33)**	**(3.18)**	**0.33**	**0.30**	**(0.51)**	**0.83**	**(2.33)**	**(5.52)**

INDRAVANI BIOTECH LTD.

Notes

1.The above financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14th February 2022 and have been subjected to Limited review by the Statutory Auditors of the Company.

2..The above results have been prepared in accordance with the Indian Accounting Standards - (Ind AS) as prescribed under Section133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter.

3. The unaudited Standalone and Consolidated financial results for the Quarter ended 31st December, 2021 being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)

3. There was one investor complaint received, resolved and disposed during the quarter.

4. Previous period figures have been regrouped wherever necessary.

Place: Chennai

Date: 14-02-2022

For Indrayani Biotech Limited



Kasiraman Sayee Sundar

Managing Director

VENKATESH & CO
Chartered Accountants

Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to the Board of Directors,
Indrayani Biotech Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended December 2021.This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (`Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Venkatesh & Co
Chartered Accountants
F.R.No.004636S

VENKATESH & CO. CHENNAI Chartered Accountants

CA Dasaraty V
Partner
M.No.026336

Place: Chennai
Date: 14th February 2022.
UDIN: 22026336ACAZFC1253.

"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai - 600 017.
Telefax : 2814 4763/64/65/66 Email : venkateshandco@gmail.com

Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI(Listing Obligations and disclosure requirements) regulations, 2015

TO THE BOARD OF DIRECTORS OF
Indrayani Biotech Limited

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **31st December, 2021** and for the period from **1st April 2021 to 31st December 2021** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended **31th December, 2020** and corresponding period from 1st April 2020 to 31st December 2020 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
The Statement includes the unaudited results of the following entities:

i. HSL Agri Solutions Private Limited – Subsidiary
ii. IBL Healthcare Private Limited – Subsidiary
iii. IBL Thiruvannamalai LLP _ Step down Subsidiary
iv. HSL Prime Properties Private Limited - Associate

Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the financial statement / financial information of **M/s. HSL Agri Solutions Private Limited** (subsidiary) included in the consolidated unaudited financial results, whose interim financial information for the Period ended 31st December, 2021 reflects total revenues of **Rs.30.66 Lakhs**, , total comprehensive profit / (loss) of **Rs 1.68 Lakhs** for the period ended on that date and in respect of **M/s. IBL Health Care Private Limited** (subsidiary) included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of **Rs.88.27 Lakhs** total net profit / (Loss) after tax of **Rs.(8.11) Lakhs**, total comprehensive profit / (loss) of **Rs.(8.11) Lakhs** for the period ended on that date, as considered in the consolidated financial results and in respect of **M/s. IBL Thiruvannamalai LLP** (stepdown subsidiary) included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of **Rs.25.55 Lakhs**, total net profit / (Loss) after tax of **Rs.(18.64) Lakhs** for the period ended on that date, as considered in the consolidated financial results.

The consolidated financial results also include the Group's share of net profit / (Loss) of **Rs.0.85 Lakhs** and total comprehensive income of **Rs. 0.85** Lakhs for the Period ended 30th September, 2021, in the consolidated financial results, in respect of **M/s. HSL Prime Properties Private Limited**, (Associate), whose financial statements / financial information have not been reviewed by us.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

For Venkatesh & Co
Chartered Accountants
F.R.No.004636S

VENKATESH & CO. CHENNAI Chartered Accountants

CA Dasaraty V
Partner
M.No.026336

Place: Chennai
Date: 14/02/2022
UDIN: 22026336ACBAXW1229.